ArticleEnvironment international2025
Aflatoxin B1 induces subtle but coordinated histone modifications in Epstein-Barr virus infected and non-infected Burkitt lymphoma cells.
Article in Environment international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Omics-Level Approaches to Studying Gammaherpesvirus Infection.Pathogens (Basel, Switzerland) · 2026Review
- Profiling histone post-translational modifications to identify signatures of epigenetic drug response in T-cell acute lymphoblastic leukemia.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Aflatoxin B1 (AFB1), a potent dietary carcinogen, and Epstein-Barr virus (EBV), an oncogenic virus, are both implicated in cancer development, particularly in endemic regions. However, the combined effects of AFB1 exposure and EBV infection on the epigenetic landscape remain poorly understood. This study investigates the impact of AFB1 and EBV on histone post-translational modifications (hPTMs) in Burkitt lymphoma (BL) cells through an integrative approach combining untargeted mass spectrometry-based profiling and a time-lapse experimental design. Our results reveal subtle, yet reproducible and dynamic alterations in histone methylation and acetylation patterns over time in all cells. Specifically, AFB1 exposure induced an increase in H3K27me3 levels, which in the case of EBV infected cells, counteracts the decrease observed at baseline compared to uninfected cells. Additionally, changes in acetylation patterns of H4 N-tail residues and key regulatory proteins suggest potential disruptions in chromatin accessibility and transcriptional regulation. Our correlation and network-based analyses further highlight coordinated epigenetic shifts in response to AFB1, with key acetylation hubs emerging within the histone PTM profile. Despite subtle differences, no significant divergence in overall hPTM responses was detected between EBV-infected and uninfected cells, emphasizing the subtlety of the EBV effect on AFB1 exposure. Future research should explore locus-specific epigenetic changes and therapeutic interventions targeting hPTMs to mitigate cancer risk associated with AFB1 exposure and EBV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.